An Open-Label Study of Azetukalner in Major Depressive Disorder
Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).